Table 2 Phenotypic and genotypic characterization results of GBS isolates
No. of isolates (%) | |
|---|---|
Drug susceptibility testing | |
Penicillin susceptible | 36/36 (100%) |
Clindamycin susceptiblea | 28/36 (78%) |
Clindamycin non-susceptibleb | 8/36 (22%) |
Erythromycin susceptible | 28/36 (78%) |
Erythromycin non-susceptible | 8/36 (22%) |
MLSB phenotype (inducible clindamycin resistance) | 3/36 (8%) |
L phenotype (clindamycin resistant, erythromycin susceptible) | 1/36 (3%) |
M phenotype (clindamycin susceptible, erythromycin resistant) | 1/36 (3%) |
Clindamycin + Erythromycin non-susceptiblea | 4/36 (11%) |
Clindamycin + Erythromycin non-susceptibleb | 7/36 (19%) |
Serotyping | |
Serotype III | 12/36 (33%) |
Serotype V | 11/36 (31%) |
Serotype Ia | 6/36 (17%) |
Serotype Ib | 2/36 (5%) |
Serotype II | 2/36 (5%) |
Serotype IV | 2/36 (5%) |
Serotype VI | 1/36 (3%) |
Multilocus sequence typing | |
ST - no exact match | 5/36 (14%) |
ST1 | 4/36 (11%) |
ST19 | 4/36 (11%) |
ST175 | 3/36 (8%) |
ST23 | 2/36 (6%) |
ST249 | 2/36 (6%) |
ST297 | 2/36 (6%) |
Other STs | 14/36 (38%) |
Phenotype association with genotype | |
Clindamycin + Erythromycin susceptible/non-susceptiblea | p = 0.0129 |
ST1 | 0/2 |
Non-ST1 | 27/2 |
Clindamycin + Erythromycin susceptible/non-susceptibleb | p = 0.0008 |
ST1 | 0/4 |
Non-ST1 | 27/3 |
MLSB phenotype negative/positive | p = 0.0060 |
ST1 | 0/2 |
Non-ST1 | 29/1 |